Raymond James & Associates Acquires 9,397 Shares of InMode Ltd. (NASDAQ:INMD)

Raymond James & Associates boosted its holdings in InMode Ltd. (NASDAQ:INMD – Get Rating) by 6.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 162,624 shares of the healthcare company’s stock after acquiring an additional 9,397 shares during the period. Raymond James & Associates’ holdings in InMode were worth $5,806,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Taylor Frigon Capital Management LLC grew its stake in InMode by 0.3% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 118,103 shares of the healthcare company’s stock valued at $3,438,000 after buying an additional 305 shares during the last quarter. National Bank of Canada FI boosted its stake in InMode by 16.5% in the 4th quarter. National Bank of Canada FI now owns 2,300 shares of the healthcare company’s stock valued at $82,000 after purchasing an additional 325 shares during the period. Anderson Hoagland & Co. boosted its stake in InMode by 0.6% in the 4th quarter. Anderson Hoagland & Co. now owns 59,611 shares of the healthcare company’s stock valued at $2,008,000 after purchasing an additional 330 shares during the period. Credit Suisse AG raised its stake in InMode by 0.4% in the 3rd quarter. Credit Suisse AG now owns 109,808 shares of the healthcare company’s stock worth $3,197,000 after purchasing an additional 393 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in InMode by 2.0% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 25,544 shares of the healthcare company’s stock worth $912,000 after acquiring an additional 499 shares during the period. Institutional investors and hedge funds own 55.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INMD. TheStreet upgraded InMode from a “c+” rating to a “b-” rating in a research note on Wednesday, April 19th. UBS Group started coverage on shares of InMode in a research note on Tuesday, March 28th. They set a “buy” rating and a $40.00 price objective on the stock. Needham & Company LLC downgraded shares of InMode from a “buy” rating to a “hold” rating in a research note on Friday, February 17th. Finally, Barclays increased their price objective on shares of InMode from $45.00 to $47.00 in a research note on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, InMode has a consensus rating of “Moderate Buy” and a consensus price target of $45.71.

InMode Trading Up 0.5 %

Shares of NASDAQ INMD opened at $33.35 on Monday. The company has a market cap of $2.77 billion, a price-to-earnings ratio of 16.59 and a beta of 2.07. InMode Ltd. has a 12 month low of $21.20 and a 12 month high of $41.84. The stock has a 50-day moving average price of $33.71 and a two-hundred day moving average price of $34.92.

InMode Company Profile

(Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.